ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AZN Astrazeneca Plc

11,368.00
100.00 (0.89%)
Last Updated: 08:33:21
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  100.00 0.89% 11,368.00 11,370.00 11,372.00 11,390.00 11,288.00 11,288.00 105,340 08:33:21
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 29.62 176.38B
Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 11,268p. Over the last year, Astrazeneca shares have traded in a share price range of 9,461.00p to 12,348.00p.

Astrazeneca currently has 1,550,189,338 shares in issue. The market capitalisation of Astrazeneca is £176.38 billion. Astrazeneca has a price to earnings ratio (PE ratio) of 29.62.

Astrazeneca Share Discussion Threads

Showing 5651 to 5673 of 6150 messages
Chat Pages: Latest  234  233  232  231  230  229  228  227  226  225  224  223  Older
DateSubjectAuthorDiscuss
12/4/2022
17:58
Had a superb run, just a bit of profit taking.
montyhedge
12/4/2022
12:44
ASTRAZENECA : Buy rating from Berenberg
04/12/2022 | 12:40pm BST

In a research note published by Luisa Hector, Berenberg advises its customers to buy the stock. The target price is revised upwards from GBX 10000 to GBX 12000.

waldron
08/4/2022
19:40
have not followed this stock for a while - what a mistake . now chart shows a NOR situation and how long is s piece of string !
arja
08/4/2022
16:27
Long term, holder, yes institutions must be piling in with new cash.
chc15
08/4/2022
16:03
Institutions I assume. I bought a fair amount, in my terms before the rise and am happily holding.
our haven
08/4/2022
15:45
I'm buying it...
mapocho
08/4/2022
14:43
Amazed there is so little chatter on this board. Up 25% in a month. Keeping entire FTSE up whilst Europe and US markets fall.But no interest here? Who is buying this?
paa65
07/4/2022
07:37
James Gordon from JP Morgan retains his positive opinion on the stock with a Buy rating.


The target price is reviewed upwards from GBX 10000 to GBX 12000.

la forge
06/4/2022
17:00
Analysts at Deutsche Bank hiked their target price for AstraZeneca shares from 10,500.0p to 11,500.0p, telling clients it saw no reason to tilt towards so-called 'value' names in the space and away from 'growth'.

Deutsche Bank conceded that an environment of rising interest rates would normally hardly be seen as auguring positively for a defensive sector to outperform.

However, DB highlighted that these weren't exactly normal times.

"This being a geopolitically-challenged stagflationary-susceptible situation, normal perhaps doesn't apply and indeed pharma has had a strong relative start to the year that may well continue," explained DB.

Within the sector, more highly-valued growth names such as AstraZeneca and Novo Nordisk had been the standout outperformers, versus the likes of GlaxoSmithKline, Novartis or Sanofi.

misca2
06/4/2022
10:09
Deutsche Bank raises AstraZeneca price target to 11,500 (10,500) pence - 'buy'
philanderer
05/4/2022
16:24
As mentioned, big momentum here, institutions buying at this level, so why sell.
chc15
05/4/2022
15:59
WD Waldron, good forecast!
dudishes
05/4/2022
07:15
Todays the day it might well break thru an important Resistence level
waldron
05/4/2022
07:14
(MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Monday its AZD8233 drug at 50-milligram dose lowered the levels of low-density lipoprotein cholesterol by 73% among people with high-risk hypercholesterolemia, meeting the main goal of a phase 2b study.

The dose-ranging clinical trial, dubbed Etesia, evaluated AZD8233 at 15 mg, 50 mg and 90 mg doses administered monthly via subcutaneous injection within a 12-week period.

Results showed that the drug also cut the PCSK9 enzyme levels by 89%, with sustained reductions observed over the dosing intervals. A decrease in PCSK9 raises LDL receptor levels, which in turn lowers cholesterol levels in the bloodstream, reducing the risk of developing heart disease.

The safety, efficacy and tolerability of AZD8233 in hypercholesterolemia are being examined in the Solano phase 2b trial, with results expected later in the year.

AstraZeneca gained nearly 1% on Monday's close.

Price (GBP): £10142.00, Change: £+66.00, Percent Change: +0.66%

waldron
31/3/2022
18:44
Mind u, mkts going down after putins demands, so taking profits not a bad thing.
chc15
31/3/2022
18:15
No harm in taking profits, but feel there is good momentum here.
chc15
31/3/2022
15:48
I'm out at £102. This is above quite a few broker PT's so happy to take profits.
Currently way above 20 mda, too high too quickly, will buy back when it settles.
Good Luck all.

beckers2008
31/3/2022
12:22
We surging here, can only mean there is strong institutional buying at this level, wow.
chc15
29/3/2022
14:09
Azn holders now in the 100 club..olaay olay olay.
hotfinance14
29/3/2022
12:31
May 2020 I said it would exceed 100 , bit premature that was , however where is our serial doomster Buywell ? Buybadly .
holts
29/3/2022
09:48
Onwards and Upwards. Let's see it can close above £100 later today.
gateside
29/3/2022
09:37
Sp through the £100 level for the first time - a bit of a landmark price!
ygor705
27/3/2022
19:39
Ianood - A split is what a meant - I got it the wrong way round!
gateside
Chat Pages: Latest  234  233  232  231  230  229  228  227  226  225  224  223  Older

Your Recent History

Delayed Upgrade Clock